Johnson & Johnson
17 of 416 with a diagram, by size
Q2 FY26 Mar 30 – Jun 28, 2026
Revenue$25.3B
+7% year over year
Gross profit$17.3B
68% margin
Operating profit$7.2B
28% margin
Net profit$5.5B
22% margin
The numbers behind the diagram
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 25.3 | 100% | +7% |
| Innovative medicine | 16.4 | 65% | +8% |
| Med tech | 8.9 | 35% | +5% |
| Cost of revenue | −8.1 | 32% | |
| Gross profit | 17.3 | 68% margin | +0pp |
| SG&A | −6.4 | 25% | +1pp |
| Other | −3.7 | 15% | +0pp |
| Operating profit | 7.2 | 28% margin | +0pp |
| Interest & other costs | −0.4 | ||
| Tax | −1.2 | ||
| Net profit | 5.5 | 22% margin | −1pp |
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 24.1 | 100% | +10% |
| Innovative medicine | 15.4 | 64% | +11% |
| Med tech | 8.6 | 36% | +8% |
| Cost of revenue | −8.1 | 34% | |
| Gross profit | 16.0 | 66% margin | +0pp |
| SG&A | −6.0 | 25% | +2pp |
| Other | −3.5 | 15% | +0pp |
| Operating profit | 6.4 | 27% margin | +0pp |
| Interest & other costs | −0.4 | ||
| Tax | −0.8 | ||
| Net profit | 5.2 | 22% margin | −28pp |
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 24.0 | 100% | +7% |
| Innovative medicine | 15.6 | 65% | +7% |
| Med tech | 8.4 | 35% | +7% |
| Cost of revenue | −7.3 | 30% | |
| Gross profit | 16.7 | 70% margin | +1pp |
| SG&A | −5.9 | 25% | +0pp |
| Other | −3.7 | 15% | +0pp |
| Operating profit | 7.1 | 30% margin | +0pp |
| Other income, net | 0.4 | ||
| Tax | −2.3 | ||
| Net profit | 5.2 | 21% margin | +9pp |
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 23.7 | 100% | +6% |
| Innovative medicine | 15.2 | 64% | +5% |
| Med tech | 8.5 | 36% | +7% |
| Cost of revenue | −7.6 | 32% | |
| Gross profit | 16.1 | 68% margin | −2pp |
| SG&A | −5.9 | 25% | −1pp |
| Other | −3.5 | 15% | +0pp |
| Operating profit | 6.7 | 28% margin | +0pp |
| Interest & other costs | −0.2 | ||
| Tax | −1.0 | ||
| Net profit | 5.5 | 23% margin | +2pp |
Financial health
The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.
The balance sheet, capital flow, debt schedule and capital structure open with a free account.
Quarter by quarter
Every set of results we hold, newest first. Open one on its own page. The arrow beside a quarter shows it in the diagram above.
| Quarter | Period | Reported | Revenue | Year over year | Operating margin | Net profit | Net margin |
|---|---|---|---|---|---|---|---|
| Q2 FY26 Mar 30 – Jun 28, 2026 reported Jul 23, 2026 Operating margin 28% Net profit $5.53B | Mar 30 – Jun 28, 2026 | Jul 23, 2026 | $25.3B | +7% | 28% | $5.53B | 22% |
| Q1 FY26 Dec 29, 2025 – Mar 29, 2026 reported Apr 22, 2026 Operating margin 27% Net profit $5.24B | Dec 29, 2025 – Mar 29, 2026 | Apr 22, 2026 | $24.1B | +10% | 27% | $5.24B | 22% |
| Q3 FY25 Jun 30 – Sep 28, 2025 reported Oct 22, 2025 Operating margin 30% Net profit $5.15B | Jun 30 – Sep 28, 2025 | Oct 22, 2025 | $24.0B | +7% | 30% | $5.15B | 21% |
| Q2 FY25 Mar 31 – Jun 29, 2025 reported Jul 24, 2025 Operating margin 28% Net profit $5.54B | Mar 31 – Jun 29, 2025 | Jul 24, 2025 | $23.7B | +6% | 28% | $5.54B | 23% |
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest